Effects of cardiovascular single pill combinations compared with identical multi-pill therapies on healthcare cost and utilization in Germany

J Comp Eff Res. 2022 Apr;11(6):411-422. doi: 10.2217/cer-2021-0197. Epub 2022 Mar 22.

Abstract

Aim: This study assessed whether a single pill combination (SPC) is associated with lower direct healthcare costs. Materials & methods: Anonymized claims data of patients ≥18 years treated with drugs for cardiovascular (CV)-related diseases either as a single pill combination or multi-pill combination (follow-up to 1 year) were evaluated. After propensity score matching, 59,336 out of 1,369,840 patients were analyzed. Results: In all cohorts, patients receiving a single pill combination had a lower frequency of general practitioner and specialist visits. The patients also had a significantly lower ratio of all-cause hospitalization days and number of CV-related prescriptions as well as all-cause prescriptions (with one exception) compared with those receiving a multi-pill combination. Conclusion: Direct CV-related costs were significantly lower in four out of seven comparisons, with a trend toward lower costs in the other three comparisons.

Keywords: cardiology/cardiovascular; comparative effectiveness research; real-world evidence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antihypertensive Agents* / therapeutic use
  • Cardiovascular Diseases* / drug therapy
  • Drug Combinations
  • Health Care Costs
  • Hospitalization
  • Humans
  • Retrospective Studies

Substances

  • Antihypertensive Agents
  • Drug Combinations